Target intelligence / Profile preview

MYC insulated genomic domain (MYC IGD)

Target
MYC IGD
Molecular classification
Genomic structure, Chromatin domain, Regulatory element
01

Overview

The MYC insulated genomic domain, also known as an insulated neighborhood, is a discrete structural unit of the genome that encapsulates the MYC proto-oncogene and its associated regulatory elements (Dowen et al., 2014). These domains are formed by DNA loops anchored by the CTCF protein and the cohesin complex, which function to restrict the activity of enhancers to specific target genes within the loop while preventing inappropriate activation by external regulatory elements (Hnisz et al., 2016). In many human cancers, the integrity of the MYC insulated genomic domain is compromised by somatic mutations or deletions that destroy the CTCF-binding boundary sites. This disruption allows neighboring super-enhancers to 'hijack' the MYC promoter, leading to constitutive MYC overexpression and oncogenic transformation (Ji et al., 2016). While the domain itself is a genomic feature rather than a protein, it is a primary focus for therapeutic strategies aimed at disrupting the transcriptional machinery it houses. Current approaches include the use of BET inhibitors like JQ1 to suppress enhancer activity within the domain and CRISPR/Cas9 technologies to repair or restore boundary elements (Schuijers et al., 2018). Understanding the spatial organization of this domain is crucial for developing precision medicines that target the epigenetic drivers of MYC-dependent malignancies.

Other names
MYC insulated neighborhoodMYC topologically associating domainMYC TADMYC regulatory domainMYC-containing chromatin loop
02

Mechanism of action

Inhibition of bromodomain-containing proteins (BET inhibitors) to disrupt super-enhancer activity within the domain; inhibition of transcriptional kinases (CDK7/9) to reduce MYC transcription; CRISPR-mediated restoration of CTCF boundary elements.

03

Biological functions

Gene expression regulationChromatin organizationTranscriptional controlEnhancer-promoter interaction
04

Disease associations

CancerT-cell acute lymphoblastic leukemiaColorectal cancerBreast cancerB-cell lymphoma
05

Safety considerations

Off-target genomic alterations from CRISPR-based therapiesDisruption of global chromatin architectureSystemic toxicity associated with BET inhibitionPotential for widespread transcriptional dysregulation of non-target genes
06

Interacting drugs

JQ1

4 more in the full profile.

07

Biomarkers

CTCF binding site mutationsMYC overexpressionSuper-enhancer signaturesChromatin accessibility (ATAC-seq)Boundary element deletion

Beyond the preview

Go deeper on MYC insulated genomic domain (MYC IGD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MYC insulated genomic domain (MYC IGD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call